adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
pharma · Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC) · TPST
Tempest Therapeutics
Tempest Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Brisbane, USA HQ
14 Employees
Public company Type
TPST · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Employees
- 14
- Programs
- 3
- Drugs
- 1
- Patents
- 10
Tempest Therapeutics pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tempest Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.